Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Corning Incorporated — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Corning Incorporated trades at $188.37 (market cap $161.49B). The key difference: Corning Incorporated is far larger — about 20.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Corning Incorporated pays a 0.6% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | GLW | |
|---|---|---|
Market Cap | $8.04B | $161.49B |
Sector | Health | Technology |
52-Week High | $339.75 | $255.79 |
52-Week Low | $241.71 | $52.52 |
Enterprise Value | $7.85B | $169.66B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Corning (GLW) trades at $183.36, down 3.92% amid a broader AI infrastructure stock selloff. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $0.70 versus $0.692 expected, marking the fourth consecutive earnings beat. Revenue growth accelerated to $15.63 billion in 2025 with net income margin improving to 10.21%. Technical indicators show bearish momentum with the price testing support at $181, while RSI at 46.51 suggests neutral momentum conditions.
GLW presents a compelling long-term opportunity with 54% analyst buy ratings and a $210.10 consensus price target representing 15% upside. Key risks include China exposure, consumer electronics cyclicality, and competitive pressures in optical communications. The company's AI partnerships with NVIDIA and Amazon position it well for sustained growth in fiber and connectivity markets despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
